"Innovative treatments in child and adolescent psychiatric disorders: from bench to bedside"

The first virtual ESCAP Research Academy

This meeting is going VIRTUAL. Due to the COVID-19 pandemic, organisers have decided to still do the meeting but over an interactive group Zoom. For this reason, we have extended the deadline for applications to June 30th 2020.

 

The 4th Research Academy was the first virtual meeting held by ESCAP, and the first time it was held in conjunction with a national congress (the Swiss Society for CAP). On the 26th August, we gathered 17 selected fellows from 9 ESCAP member countries to attend. All attendees were clinician-scientists in their early career of being a child and adolescent psychiatrist (CAP).

The aims of the Research Academy are to form an international collaboration of clinician-scientists across Europe, for them to share experience and work with leading senior research CAPs, and work together on collaborative projects.

This year’s theme delivered through the four international experts in the field was on translational psychiatric neuroscience.

Marie Schaer, professor at the University of Geneva, gave a fascinating overview of her projects on eye-tracking & brain imaging indicating that early intervention as young as 6-9 months of age can improve social deficits in ASD children.

Edna Grünblatt, professor at the University of Zurich, delivered the second talk on induced pluripotent stem cells (iPSC) in modelling neurodevelopmental disorders, specifically, she discussed patient-specific iPSC in ADHD and the proliferation differences that could be related to Wnt-signalling.

Thomas Wiese from Roche took us through the drug discovery stages, while Brenda Vincenzi introduced Angelman Syndrome & a current phase 1 clinical trial testing a novel drug targeting the gene associated with the syndrome.

Johannes Hebebrand, professor at the University of Duisburg-Essen, head of the Research Academy and Research division, and Editor-in-chief of ECAP, spoke of a case series of anorexia patients treated with a leptin-targeted drug. The drug not only changes the patients perception to food but improved mood, emotions & hyperactivity.

Late afternoon, three short presentations from Dr Mercedes Huscsava on her project of transition to teletheraphy for adolescents during the COVID-19 pandemic, Dr Kotsis Konstantinos and Dr Asilay ?eker introduced the new ESCAP committee for Early Career and Trainees in CAP, lastly, Dr Paul Klauser (senior advisor of the Research Academy) and Dr Alexis Revet (junior advisor of the Research Academy) gave an overview of the initial findings of the CovCAP survey launched in April to determine the state of CAP services in Europe during the pandemic.

ESCAP President and board would like to thank all the organisers for their time and effort to create an interactive and virtual event. Also, thanks go to the expert presenters for their fascinating insights into their research fields and to the attendees for their enthusiasm and drive to be part of this community.

We’ll be updating our ESCAP events calendar soon, so keep an eye out for more events like this.

 

Call for participants

The 2020 Research Academy meeting of the European Society for Child and Adolescent Psychiatry (ESCAP) will take place on the 26-27th August using a virtual platform.

The aims of our annual meetings are to promote research excellence and collaborative work among young clinician-scientists in the field of child and adolescent psychiatry (CAP). The ESCAP Research Academy wishes to support early careers by promoting training, encouraging collaborations and by providing a forum to share experiences with senior world leading researchers in psychiatry.

Our next meeting will focus on “Innovative treatments in child and adolescent psychiatric disorders: from bench to bedside”. Four international experts in the field of child and adolescent mental health will present their work. Johannes Hebebrand will present on leptin and anorexia nervosa. Marie Schaer will give a lecture on new tools for the early detection of autism spectrum disorder (ASD). Edna Grünblatt will present on how induced pluripotent stem cells (iPSC) can be used to model neurodevelopemental disorders such as ADHD. Brenda Vincenzi and Thomas Wiese from Roch pharmaceutical company will share their experience on drug development for ASD.

Fellows will also be invited to join a special pre-congress course designed for Swiss CAP in training and led by Bruno Falissard and Johannes Hebebrand.

This 1 and a half-day meeting will be chaired by two clinician-scientists, Dr Paul Klauser and Dr Alexis Revet, and by Professor Johannes Hebebrand, editor-in-chief of European Child + Adolescent Psychiatry (ECAP) and head of the ESCAP Research Division, in the presence of Laura Kehoe, ESCAP communication editor. Attendees will be asked to collaborate within a network after the meeting to tackle a research question at the European level (see Barrett et al. Eur Child Adolesc Psychiatr 2020; Revet et al. Eur Child Adolesc Psychiatr 2018).

Requirements for participation are the following:

  • Trainee or <5 years after completion of training in child and adolescent psychiatry or child and adolescent clinical psychology;
  • At least one first-authored paper published or in press in a peer-reviewed journal indexed in Pubmed;
  • Submission of an abstract for a short presentation of your research at the Research Academy meeting;
  • Submission of a cover letter highlighting your academic perspectives;
  • Fluency in English.

Please send your application using the following link before the 30th June 2020. Selected participants will be advised on the 15th July 2020.